1-(10h-phenothiazin-2-yl)ethanone is the chemical name for **2-Acetylphenothiazine**. It's a relatively simple organic compound with a phenothiazine core structure and an acetyl group attached at the 2-position.
**Importance in Research:**
While 2-Acetylphenothiazine itself might not be directly studied extensively, its **structural similarity to other phenothiazine derivatives** makes it an important compound in research. Here's why:
* **Phenothiazine Core:** This core structure is found in a wide range of compounds with important biological activity.
* **Antipsychotic Drugs:** Many phenothiazine derivatives are used as **antipsychotic drugs**, like chlorpromazine and promethazine.
* **Antihistamines:** Some phenothiazines also act as antihistamines, used for allergic reactions.
* **Lead Compound:** 2-Acetylphenothiazine might act as a **starting point for synthesizing new derivatives**, which could potentially be studied for:
* **Improved therapeutic properties** compared to existing drugs.
* **Novel biological activities** for treating different conditions.
* **Mechanistic Studies:** Studying the reactions of 2-Acetylphenothiazine with various reagents could help researchers understand the **chemical and pharmacological properties** of the phenothiazine core.
**Therefore, 2-Acetylphenothiazine, while not a blockbuster drug itself, holds significance in research due to its potential for:**
* **Drug development**
* **Understanding the properties of phenothiazines**
* **Developing new therapeutic agents.**
However, it's crucial to note that **research on this specific compound is limited**, and its potential applications are still under investigation.
1-(10H-phenothiazin-2-yl)ethanone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 81131 |
| CHEMBL ID | 407734 |
| CHEBI ID | 92473 |
| SCHEMBL ID | 342449 |
| MeSH ID | M000606663 |
| Synonym |
|---|
| BIDD:GT0700 |
| nsc-169669 |
| ethanone, 1-(10h-phenothiazin-2-yl)- |
| 3-acetylphenothiazine |
| nsc169669 |
| 6631-94-3 |
| 2-acetylphenothiazine |
| nsc-57951 |
| nsc57951 |
| MLS000047624 , |
| smr000033635 |
| 1-(10h-phenothiazin-2-yl)ethanone |
| inchi=1/c14h11nos/c1-9(16)10-6-7-14-12(8-10)15-11-4-2-3-5-13(11)17-14/h2-8,15h,1h |
| AK-968/41128722 |
| STK301831 |
| 2-acetylphenothiazine, 95% |
| SR-01000597201-3 |
| ml171 |
| AC-11153 |
| CHEMBL407734 |
| SR-01000597201-6 |
| sr-01000597201 |
| SR-01000597201-4 |
| AKOS000119447 |
| nsc 169669 |
| einecs 229-626-4 |
| nsc 57951 |
| methyl phenothiazin-2-yl ketone |
| 8dee7h3xab , |
| unii-8dee7h3xab |
| MLS003166900 |
| HMS2301E19 |
| FT-0610945 |
| S5304 |
| SCHEMBL342449 |
| 1-(10h-phenothiazin-2-yl)ethan-1-one |
| BS-4506 |
| cid_81131 |
| bdbm42323 |
| ml 171 |
| 1-(10h-phenothiazin-2-yl)ethanone # |
| AC-33136 |
| DTXSID20216525 |
| SR-01000597201-1 |
| CHEBI:92473 |
| mfcd00005017 |
| HY-12805 |
| CS-0012526 |
| 2-acetylphenothiazine;2-apt |
| Q27164209 |
| HMS3869J13 |
| CCG-266883 |
| 2-acetylphenothiazine (ml171) |
| 2-acetylphenothiazine; methyl phenothiazin-2-yl ketone; labotest-bb lt00012652; 2-acetyl-phenothiazine |
| A867484 |
| EN300-20519 |
| ketone, methyl phenothiazin-2-yl |
| 1-(10h-phenothiazin-2-yl)-1-ethanone |
| Z104478550 |
| SY050939 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The safe dose of single IP ML171 in ICR mice was 250 mg/kg or less." | ( Single-Dose Toxicity Study on ML171, a Selective NOX1 Inhibitor, in Mice. Ahn, JS; Cho, JH; Choi, JY; Jung, HY; Kim, CD; Kim, YJ; Kim, YL; Lim, JH; Oh, EJ; Oh, SH; Park, SH; Yook, JM, 2021) | 0.62 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Exploiting the secondary activity of marketed drugs, on the other hand, may help in generating drug leads that can be optimized for the observed side-effect target, while maintaining acceptable bioavailability and toxicity profiles." | ( Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Abagyan, R; Bisson, WH; Bruey-Sedano, N; Cheltsov, AV; Chen, J; Christopoulos, A; Dalton, JT; Goldberger, N; Lin, B; May, LT; Sexton, PM; Zhang, XK, 2007) | 0.34 |
| Class | Description |
|---|---|
| phenothiazines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 25.1189 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| beta-amyloid peptide, A beta {N-terminal} [human, cerebrospinal fluid, conditioned medium of mixed-brain cell cultures, Peptide Partial, 33 aa] | Homo sapiens (human) | Potency | 9.0200 | 0.1500 | 4.5375 | 9.0200 | AID956 |
| ClpP | Bacillus subtilis | Potency | 31.6228 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 10.8903 | 31.5287 | AID504466 |
| TDP1 protein | Homo sapiens (human) | Potency | 12.9953 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 4.3534 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468; AID911 |
| alpha synuclein, partial | Homo sapiens (human) | Potency | 5.9841 | 0.1515 | 3.7637 | 6.2864 | AID937 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 2.8184 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 31.3814 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 67.4555 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 11.2202 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
| Glutamate receptor ionotropic, kainate 1 | Rattus norvegicus (Norway rat) | Potency | 5.9841 | 0.1515 | 3.7637 | 6.2864 | AID937 |
| Glutamate receptor ionotropic, kainate 2 | Rattus norvegicus (Norway rat) | Potency | 5.9841 | 0.1515 | 3.7637 | 6.2864 | AID937 |
| Glutamate receptor ionotropic, kainate 3 | Rattus norvegicus (Norway rat) | Potency | 5.9841 | 0.1515 | 3.7637 | 6.2864 | AID937 |
| Glutamate receptor ionotropic, kainate 4 | Rattus norvegicus (Norway rat) | Potency | 5.9841 | 0.1515 | 3.7637 | 6.2864 | AID937 |
| Leukotriene B4 receptor 1 | Homo sapiens (human) | Potency | 7.7300 | 0.1800 | 3.9550 | 7.7300 | AID911 |
| Glutamate receptor ionotropic, kainate 5 | Rattus norvegicus (Norway rat) | Potency | 5.9841 | 0.1515 | 3.7637 | 6.2864 | AID937 |
| Leukotriene B4 receptor 2 | Homo sapiens (human) | Potency | 7.7300 | 0.1800 | 3.9550 | 7.7300 | AID911 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| NADPH oxidase 1 | Homo sapiens (human) | IC50 (µMol) | 1.5087 | 0.0440 | 1.2609 | 5.5000 | AID2538; AID2808; AID435002; AID435009 |
| rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 (µMol) | 31.6400 | 7.3900 | 57.8904 | 301.2400 | AID624330 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Lysosomal acid glucosylceramidase | Homo sapiens (human) | EC50 (µMol) | 50.0000 | 2.5000 | 2.5000 | 2.5000 | AID1268 |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.3300 | 1.2650 | 2.2000 | AID1268 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| lysosome | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| lysosomal membrane | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| endoplasmic reticulum | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| Golgi apparatus | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| trans-Golgi network | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| lysosomal lumen | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| extracellular exosome | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| plasma membrane | Leukotriene B4 receptor 1 | Homo sapiens (human) |
| plasma membrane | Leukotriene B4 receptor 1 | Homo sapiens (human) |
| nucleoplasm | Leukotriene B4 receptor 2 | Homo sapiens (human) |
| plasma membrane | Leukotriene B4 receptor 2 | Homo sapiens (human) |
| membrane | Leukotriene B4 receptor 2 | Homo sapiens (human) |
| plasma membrane | Leukotriene B4 receptor 2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1727546 | Inhibition of erastin-induced ferroptosis in human HT-1080 cells assessed as cell viability incubated for 48 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209 | Structure-activity relationship studies of phenothiazine derivatives as a new class of ferroptosis inhibitors together with the therapeutic effect in an ischemic stroke model. |
| AID327647 | Inhibition of wild type androgen receptor expressed in CV1 cells assessed as dihydrotestosterone-stimulated transactivation at 500 nM by CAT reporter gene assay | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jul-17, Volume: 104, Issue:29 | Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.98) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||